Are all low molecular weight heparins equivalent in the management of venous thromboembolism?

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 4, 2008, Pages 385-392

  Fareed, Jawed ^a   Jeske, Walter ^a   Fareed, Daniel ^a   Clark, Melaine ^a   Wahi, Rakesh ^a   Adiguzel, Cafer ^a   Hoppensteadt, Debra ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Deep vein thrombosis; Low molecular weight heparins; Pulmonary embolism; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; HEPARIN LYASE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NITRIC ACID; PROTHROMBIN A; REVIPARIN; THROMBIN; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR; WARFARIN;

ACUTE DISEASE; ANTICOAGULATION; ARTICLE; BENZYLATION; BLEEDING; CANCER PATIENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEPOLARIZATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; FIBRINOLYSIS; HEALTH CARE ORGANIZATION; HEMATOMA; HUMAN; HYDROLYSIS; MOLECULAR WEIGHT; MONOTHERAPY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SKIN BRUISING; THROMBOSIS PREVENTION; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PULMONARY EMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 51849107776     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608319881     Document Type: Article

References (56)

1. Hirsh J., Warkentin TE, Raschke R., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998 ; 114: 489S.
2. Aguilar D., Goldhaber SZ Clinical use of low-molecular-weight heparins. Chest. 1999 ; 115: 1418-1423.
3. Weitz JI Low-molecular-weight heparins. N Engl J Med. 1997 ; 337: 688.
4. Bijsterveld NR, Hettiarachchi R., Peters R., et al. Low-molecular weight heparins in venous and arterial thrombotic disease. Thromb Haemost. 1999 ; 82 (Suppl 1). 139.
5. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999 ; 130: 800.
6. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000 ; 160: 181.
7. Koch A., Ziegler S., Breitschwerdt H., Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thromb Res. 2001 ; 102: 295.
8. Mismetti P., Laporte S., Darmon JY, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001 ; 88: 913.
9. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004 ;(4). CD001100.
10. Lim W., Dentali F., Eikelboom JW, Crowther MA Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006 ; 144: 673.
11. Maddineni J., Walenga JM, Jeske WP, et al. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Clin Appl Thromb Hemost. 2006 ; 12: 267.
12. Fareed J., Hoppensteadt D., Jeske W., et al. The available low molecular weight heparin preparations are not the same. Clin Appl Thrombosis/Hemostasis. 1997 ; 3 (Suppl 1). S38.
13. Hirsh J. Heparin. N Engl J Med. 1991 ; 324: 1565.
14. van der Heijden JF, Prins MH, Büller HR For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? Thromb Res. 2000 ; 100: V121.
15. Fareed J., Jeske W., Hoppensteadt D., et al. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol. 1998 ; 82: 3L.
16. Fareed J., Ma Q., Florian M., et al. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. Semin Thromb Hemost. 2004 ; 30 (Suppl 1). 89.
17. Handeland GF, Abildgaard U., Holm HA, Arnesen KE Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol. 1990 ; 39: 107.
18. Büller HR, Agnelli G., Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126: 401S.
19. Harker LA, Hanson SR, Runge MS Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol. 1995 ; 75: 12B.
20. Andersson L-O., Barrowcliffe TW, Holmer E., et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res. 1979 ; 15: 531.
21. Eriksson BI, Söderberg K., Widlund L., et al. A comparative study of 3 low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost. 1995 ; 73: 398.
22. White RH, Ginsberg JS Low-molecular-weight heparins: are they all the same ? Br J Haematol. 2003 ; 121: 12-20.
23. Bick RL, Fareed J. Low molecular weight heparins: differences and similarities in approved preparations in the United States. Clin Appl Thrombosis/Haemostasis. 1999 ; 5 (Suppl 1). S63.
24. Beguin S., Welzel D., Al Dieri R., Hemker HC Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor Xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis. 1999 ; 29: 170-178.
25. Broze GJ Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis. 1995 ; 6 (Suppl 1). S7.
26. Brodin E., Svensson B., Paulssen RH, et al. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment. J Lab Clin Med. 2004 ; 144: 246.
27. Hansen JB, Sandset PM, Huseby KR, et al. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol. 1998 ; 101: 638.
28. Montalescot G., Collet JP, Lison L., et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol. 2000 ; 36: 110.
29. Hodl R., Huber K., Kraxner W., et al. Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol. 2002 ; 89: 589.
30. Fletcher JP, Ao PY, Hawthorne WJ Antiproliferative effects of low molecular weight heparin. ANZ J Surg. 2004 ; 74: 793.
31. van den Belt AG, Prins MH, Lensing AW, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2000 ; (2). CD001100.
32. Segal JB, Streiff MB, Hofmann LV Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med. 2007 ; 146: 211.
33. McCart GM, Kayser SR Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother. 2002 ; 36: 1042.
34. Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2005 ; 165: 733.
35. Snow V., Qaseem A., Barry P., et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2007 ; 146: 204.
36. Nicolaides AN, Fareed J., Kakkar AK, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006 ; 25: 101.
37. Hull R., Pineo GF, Mah AF, et al. Safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal-vein thrombosis using subcutaneous low-molecular-weight heparin versus warfarin. Thromb Haemost. 2001 ;(Suppl): abstract OC1647.
38. Hull RD, Pineo GF, Mah AF, Brant RF, for the LITE Study Investigators. A randomized trial evaluating long-term low-molecular-weight heparin therapy for 3 months versus intravenous heparin followed by warfarin sodium [abstract]. Blood. 2002 ; 100: 148a, abstract 556.
39. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 ; 119: 1062.
40. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 ; 349: 146.
41. Levitan N., Dowlati A., Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999 ; 78: 285.
42. Kakkar AK, DeRuvo N., Chinswangwatanakul V., et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 1995 ; 346: 1004-1005.
43. Levine MN Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost. 1997 ; 78: 133.
44. Pini M., Spyropoulos AC Prevention of venous thromboembolism. Semin Thromb Hemost. 2006 ; 32: 755.
45. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126: 338S.
46. Planès A., Vochelle N., Fagola M., Bellaud M. ; the Reviparin Study Group. Comparison of 2 low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Blood Coag Fibrinol. 1998 ; 9: 499.
47. Planès A., Samama MM, Lensing AW, et al. Prevention of deep vein thrombosis after hip replacement: comparison between 2 low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999 ; 81: 22.
48. TIFDED Study Group. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin, and dalteparin. Haemostasis. 1999 ; 29: 310.
49. Palmer AJ, Koppenhagen K., Kirchhof B., et al. Efficacy and safety of low molecular weight heparin, unfractionated heparin, and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomized clinical trials. Haemostasis. 1997 ; 27: 75-84.
50. Freedman KB, Brookenthal KR, Fitzgerald RH, et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000 ; 82A: 929.
51. Westrich GH, Haas SB, Mosca P., Peterson M. Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty. J Bone Joint Surg Br. 2000 ; 82: 795.
52. Nightingale SL From the Food and Drug Administration. Appropriate use of low-molecular-weight heparins (LMWHs). JAMA. 1993 ; 270: 1672.
53. Leong W., Hoppensteadt DA Generic forms of low-molecular-weight heparins: some practical considerations. Clin Appl Thromb Hemost. 2003 ; 9: 293.
54. Fareed J., Bick RL Are the current guidelines for the acceptance of generic low molecular weight heparins adequate ? Clin Appl Thromb Hemost. 2003 ; 9: 269.
55. Kishimoto TK, Viswanathan K., Ganguly T. et al. Contaminated heparin associated with adverse clinical effects and activation of the contact system. NJ Med published at www.nejm.org, April 23, 2008.
56. Hoppensteadt DA, Wahi R., Adiguzel C., et al. Contaminant in the recalled unfractionated heparin preparations: where is the problem? Clin Appl Thromb and Hemost, in press, 2008.